How Lysosomal Storage Diseases Market Will Dominate in Coming Years? Key Players: Shire, Pfizer, Sanofi, BioMarin Pharmaceutical Inc., Amicus Therapeutics

The Global Lysosomal Storage Diseases Therapeutics Market Has Been Segmented On The Basis Of Indication (Gaucher's Diseases, Fabry Diseases, Pompe’s Syndrome, Mucopolysaccharidosis, Others); Type Of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, Others); End User (Hospitals, Clinics); And Region (North America, Latin America, Europe, Asia Pacific (APAC), And Middle East & Africa (MEA)).

Persistence Market Research delivers key insights on the global lysosomal storage diseases therapeutics market in a new report titled, “Lysosomal Storage Diseases Therapeutics Market: Global Industry Analysis and Forecast, 2016–2026”. In terms of revenue, the global lysosomal storage diseases therapeutics market is projected to register a healthy CAGR of 10.0% over the forecast period and is estimated to be valued at US$ 14.36 Bn by 2026. In the report, Persistence Market Research analyzes the key factors and trends impacting the growth and performance of the global lysosomal storage diseases therapeutics market over the forecast period.

Request Sample of This Report @ https://www.persistencemarketresearch.com/samples/3145

An increasing diagnosis rate due to increasing awareness and financial incentives for orphan drug de-velopment to recover R&D costs is the primary factor fueling the growth of the global lysosomal storage diseases therapeutics market. Also, an increasing focus of major biopharmaceutical companies on the research and development of drugs for the treatment of rare diseases is expected to boost the global lysosomal storage diseases therapeutics market during the forecast period. Moreover, the number of treatment options currently in the pipeline is further expected to bolster revenue growth of the global lysosomal storage diseases therapeutics market during the forecast period.

Shire PLC, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., and Amicus Therapeutics, Inc. are some of the companies operat-ing in the global lysosomal storage diseases therapeutics market. Top market players are investing in focused R&D initiatives to develop innovative products for the treatment of rare diseases and are look-ing to drive growth in established markets through strategic partnerships, collaborations, and acquisi-tions. The report discusses individual strategies of these companies in terms of increasing focus on rare diseases, initiatives to increase awareness, and enhancing distribution base. The report concludes with strategic recommendations for players already present in the market and new players planning to enter the global lysosomal storage diseases therapeutics market.

However, heterogeneity of the disease leading to underdiagnoses of lysosomal storage diseases, lack of treatment options, and high cost of treatment are factors likely to hamper the growth of the global lysosomal storage diseases therapeutics market over the forecast period.

Advent of therapies targeting neuropathic manifestations by crossing blood brain barrier (BBB) and therapies that overcome immune response and have better tissue selectivity will define the future land-scape of the global lysosomal storage diseases therapeutics market.

Request For Methodology @ https://www.persistencemarketresearch.com/methodology/3145

The Gaucher's Diseases indication segment is estimated to account for 29.7% revenue share of the global lysosomal storage diseases therapeutics market by 2016 end. The Enzyme Replacement Thera-py segment was valued at US$ 4,833.8 Mn in 2015 and is expected to exhibit the highest CAGR of 10.0% over the forecast period to reach US$ 13.58 Bn by 2026 end. The Hospitals end user segment is expected to witness 2.8X increase in revenue over the forecast period and is expected to create absolute $ opportunity of US$ 346.2 Mn in 2017 over 2016.
Among regions, Europe is expected to be the dominant regional market in the global lysosomal storage diseases therapeutics market during the forecast period.

The Europe market accounted for the highest revenue share of 34.8% and was valued at US$ 1,773.2 Mn in 2015; and is expected to witness a CAGR of 10.2% during the forecast period. North America is expected to be the second most lucrative market in the global lysosomal storage diseases therapeutics market and is estimated to represent ab-solute $ opportunity of US$ 159.6 Mn in 2017 over 2016.

4. Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.3. Restraints
4.4. Opportunity
4.5.Forecast Factors – Relevance and Impact
4.6. Reimbursement Scenario in U.S.
4.7. Pipeline Analysis

5. Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecasts, By Therapy
5.1. Introduction
5.2. Basis Point Share (BPS) Analysis By Therapy Type
5.3. Y-o-Y Growth Projections By Therapy Type
5.4. Market Value Forecast By Therapy , 2015–2026
5.4.1. Enzyme Replacement Therapy

5.4.2. Stem-cell Therapy
5.4.3. Substrate Reduction Therapy
5.4.4. Others
5.5. Market Attractiveness By Therapy

6. Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecasts, By Indication
6.1. Introduction
6.2. Basis Point Share (BPS) Analysis By Treatment Type
6.3. Y-o-Y Growth Projections By Treatment Type
6.4. Market Value Forecast By Indication , 2015–2026
6.4.1. Gaucher's Disease

6.4.2. Fabry Disease
6.4.3. Pompe’s Syndrome
6.4.4. Mucopolysaccharidosis
6.4.5. Others
6.5. Market Attractiveness By Indication

7. Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecasts, By End User
7.1. Introduction
7.2. Basis Point Share (BPS) Analysis By Treatment Type
7.3. Y-o-Y Growth Projections By Treatment Type
7.4. Market Value Forecast By End User , 2017–2027

7.4.1. Hospitals
7.4.2. Clinics
7.5. Market Attractiveness By End User

8. Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecasts, By Region
8.1. Basis Point Share (BPS) Analysis By Country
8.2. Y-o-Y Growth Projections By Country
8.3. Market Value Forecast By Region

8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia-Pacific (APAC)
8.3.5. Middle East & Africa (MEA)
8.4. Market Attractiveness By Country/Region

9. North America Lysosomal Storage Diseases Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis By Country
9.1.2. Y-o-Y Growth Projections By Country
9.2. Market Value Forecast By Country , 2015–2026

9.2.1. US
9.2.2. Canada
9.3. Market Value Analysis and Forecast By Country & End User, 2015–2026
9.4. Market Value Forecast By Type of Therapy , 2015–2026
9.4.1. Enzyme Replacement Therapy
9.4.2. Stem Cell Therapy
9.4.3. Substrate Reduction Therapy
9.4.4. Others

9.5. Market Value Forecast By Indication , 2015–2026
9.5.1. Gaucher's Disease
9.5.2. Fabry Disease
9.5.3. Pompe’s Syndrome
9.5.4. Mucopolysaccharidosis
9.5.5. Others
9.6. Market Attractiveness Analysis

Full Information@ https://www.persistencemarketresearch.com/market-research/lysosomal-storage-diseases-market.asp

ABOUT US:
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

CONTACT:
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.